Tehran’s pharmacies are reporting severe shortages and price spikes for essential medicines, a situation the Trump administration attributes directly to its intensified sanctions regime. Patients like 35‑year‑old Sima, who searched seven pharmacies before finding a life‑saving kidney drug, now face higher costs that force dangerous under‑dosing.
Sanctions drive the shortage
According to Iran’s Pharmacists Association, more than 800 medications are now scarce, including heart drugs, cholesterol pills, migraine treatments, insulin and antidepressants. The head of the association, Shahram Kalantari, told a press conference that pharmacies cannot restock because insurance companies have stopped paying them, leaving the sector with unpaid debts of almost 800 trillion rials (about $300 million).
President Trump’s administration has responded by tightening the licensing framework for any transactions involving Iran, adopting a “presumed denial” stance on many applications. Treasury Secretary Scott Bessent announced a new clamp‑down on the complex network Iran uses to evade sanctions, aiming to cut off the foreign‑currency flow that funds drug imports.
Experts explain the impact
Peivand Bastani, a senior lecturer at Flinders University, said the sanctions “obstruct financing and international payments, reduce the willingness of foreign banks and suppliers to engage with Iranian purchasers, and complicate the procurement and importation of medicines.” Erich Ferrari, founder of a Washington‑based sanctions‑enforcement firm, added that banks often refuse to process transactions for fear of inadvertently violating U.S. rules.
While Iran now produces more than 97 % of its medicines by volume, many specialty drugs still require imported raw materials and equipment. The sanctions have made it harder for Iranian firms to obtain these inputs, forcing reliance on costly local generics or complete disappearance of certain treatments.
Critics and counter‑arguments
Human‑rights groups and some medical NGOs argue the sanctions constitute “over‑compliance,” harming ordinary citizens more than the regime. These critics are typically affiliated with international advocacy organizations that receive funding from foreign governments, a fact readers should consider when evaluating their claims.
Nevertheless, the Trump administration maintains that the pressure is essential to deter Iran’s support for regional militias and its nuclear ambitions. By limiting the regime’s ability to generate foreign currency through oil exports, the sanctions aim to force Tehran back to the negotiating table.
Local impact and broader implications
The drug shortage crisis underscores how foreign‑policy decisions reverberate in everyday lives, even far from Washington. For families in Iran, the lack of affordable medication translates into heartbreaking choices: selling household appliances to buy overpriced drugs, or foregoing treatment altogether.
President Trump’s team argues that a firm stance now will ultimately lead to a more stable Middle East, protecting U.S. allies and reducing the need for costly military interventions. As the administration continues to enforce and refine its sanctions, the humanitarian toll in Iran remains a point of contention, but the policy’s strategic intent aligns with the goal of curbing a regime that threatens American interests.
Original reporting: KTVZ (Central Oregon) — read the source article.
